Peloruside A is a Microtubule-stabilizing Agent with Exceptional Anti-migratory Properties in Human Endothelial Cells

Overview

Journal Oncoscience

Specialty Oncology

Date 2015 Aug 6

PMID 26244166

Citations 11

Authors

Anutosh Ganguly

Fernando Cabral

Hailing Yang

Kamala D Patel

Affiliations

Soon will be listed here.

Abstract

Peloruside A is a novel antimitotic drug originally isolated from the marine sponge Mycale hentschieli. Previous studies showed that peloruside A stabilizes microtubules by binding to a site on tubulin distinct from paclitaxel, another microtubule stabilizing drug. Peloruside A blocks mitosis, but little is known about the effects on other cellular activities. Here we report that peloruside A is the most potent microtubule inhibitor yet tested for its ability to block endothelial cell migration. Quantitative analysis indicated that it inhibits microtubule dynamics and endothelial cell migration at 1/200(th) of the concentration needed to inhibit cell division (the cytotoxic concentration), indicating that it could potentially have a large margin of safety when used to specifically target angiogenesis. By comparison, paclitaxel, a well-known cancer therapeutic drug, suppresses cell migration at 1/13(th) of its cytotoxic concentration; and vinblastine suppresses cell migration at just slightly below its cytotoxic antimitotic concentration. Thus, different microtubule targeted drugs have varying relative potencies for inhibition of cell migration versus cell division. The results suggest that peloruside A may be an especially useful agent for anti-angiogenesis therapy and point to the likelihood that other antimitotic drugs might be found with an even larger potential margin of safety.

Citing Articles

Pelophen B is a non-taxoid binding microtubule-stabilizing agent with promising preclinical anticancer properties.

Vermeulen S, Ernst S, Blondeel E, Xia Z, Rappu P, Heino J Sci Rep. 2024; 14(1):30188.

PMID: 39633082 PMC: 11618378. DOI: 10.1038/s41598-024-80672-z.

Effects of Paclitaxel on Plasma Membrane Microviscosity and Lipid Composition in Cancer Cells.

Shimolina L, Gulin A, Khlynova A, Ignatova N, Druzhkova I, Gubina M Int J Mol Sci. 2023; 24(15).

PMID: 37569560 PMC: 10419023. DOI: 10.3390/ijms241512186.

Resistance to anti-tubulin agents: From vinca alkaloids to epothilones.

Krause W Cancer Drug Resist. 2022; 2(1):82-106.

PMID: 35582143 PMC: 9019178. DOI: 10.20517/cdr.2019.06.

The Frequent Sampling of Wound Scratch Assay Reveals the "Opportunity" Window for Quantitative Evaluation of Cell Motility-Impeding Drugs.

Kauanova S, Urazbayev A, Vorobjev I Front Cell Dev Biol. 2021; 9:640972.

PMID: 33777948 PMC: 7991799. DOI: 10.3389/fcell.2021.640972.

Anti-migratory effects of Piper betle leaf aqueous extract on cancer cells and its microtubule targeting properties.

Looi M, Wong A, Gnapragasan S, Japri A, Rajedadram A, Pin K J Zhejiang Univ Sci B. 2020; 21(9):745-748.

PMID: 32893531 PMC: 7519629. DOI: 10.1631/jzus.B2000278.

References

Hood K, West L, Rouwe B, Northcote P, Berridge M, Wakefield S . Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity. Cancer Res. 2002; 62(12):3356-60. View

Monzo M, Rosell R, Sanchez J, Lee J, OBrate A, Gonzalez-Larriba J . Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol. 1999; 17(6):1786-93. DOI: 10.1200/JCO.1999.17.6.1786. View

Ganguly A, Yang H, Zhang H, Cabral F, Patel K . Microtubule dynamics control tail retraction in migrating vascular endothelial cells. Mol Cancer Ther. 2013; 12(12):2837-46. PMC: 4011668. DOI: 10.1158/1535-7163.MCT-13-0401. View

Kavallaris M, Kuo D, Burkhart C, Regl D, Norris M, Haber M . Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 1997; 100(5):1282-93. PMC: 508306. DOI: 10.1172/JCI119642. View

Kapoor S, Panda D . Kinetic stabilization of microtubule dynamics by indanocine perturbs EB1 localization, induces defects in cell polarity and inhibits migration of MDA-MB-231 cells. Biochem Pharmacol. 2012; 83(11):1495-506. DOI: 10.1016/j.bcp.2012.02.012. View

Zeng Z, Inoue K, Sun H, Leng T, Feng X, Zhu L . TRPM7 regulates vascular endothelial cell adhesion and tube formation. Am J Physiol Cell Physiol. 2014; 308(4):C308-18. PMC: 4329423. DOI: 10.1152/ajpcell.00275.2013. View

Jordan M, Thrower D, Wilson L . Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci. 1992; 102 ( Pt 3):401-16. DOI: 10.1242/jcs.102.3.401. View

Torin Huzil J, Chik J, Slysz G, Freedman H, Tuszynski J, Taylor R . A unique mode of microtubule stabilization induced by peloruside A. J Mol Biol. 2008; 378(5):1016-30. PMC: 2441936. DOI: 10.1016/j.jmb.2008.03.026. View

Arnaoutova I, George J, Kleinman H, Benton G . The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis. 2009; 12(3):267-74. DOI: 10.1007/s10456-009-9146-4. View

10.

Ganguly A, Yang H, Cabral F . Paclitaxel-dependent cell lines reveal a novel drug activity. Mol Cancer Ther. 2010; 9(11):2914-23. PMC: 2978777. DOI: 10.1158/1535-7163.MCT-10-0552. View

11.

Kanakkanthara A, Wilmes A, OBrate A, Escuin D, Chan A, Gjyrezi A . Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes. Mol Cancer Ther. 2011; 10(8):1419-29. PMC: 3158586. DOI: 10.1158/1535-7163.MCT-10-1057. View

12.

Jordan M, Wilson L . Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004; 4(4):253-65. DOI: 10.1038/nrc1317. View

13.

Cabral F, Abraham I, Gottesman M . Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in alpha-tubulin. Proc Natl Acad Sci U S A. 1981; 78(7):4388-91. PMC: 319795. DOI: 10.1073/pnas.78.7.4388. View

14.

Jordan M, Wilson L . Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol. 1998; 10(1):123-30. DOI: 10.1016/s0955-0674(98)80095-1. View

15.

Ganguly A, Yang H, Sharma R, Patel K, Cabral F . The role of microtubules and their dynamics in cell migration. J Biol Chem. 2012; 287(52):43359-69. PMC: 3527923. DOI: 10.1074/jbc.M112.423905. View

16.

Best H, Matthews J, Heathcott R, Hanna R, Leahy D, Coorey N . Laulimalide and peloruside A inhibit mitosis of Saccharomyces cerevisiae by preventing microtubule depolymerisation-dependent steps in chromosome separation and nuclear positioning. Mol Biosyst. 2013; 9(11):2842-52. DOI: 10.1039/c3mb70211a. View

17.

Evans D, Welch D, Speed A, Moniz G, Reichelt A, Ho S . An aldol-based synthesis of (+)-peloruside a, a potent microtubule stabilizing agent. J Am Chem Soc. 2009; 131(11):3840-1. PMC: 3357919. DOI: 10.1021/ja900020a. View

18.

Zacherl J, Hamilton G, Thalhammer T, Riegler M, Cosentini E, Ellinger A . Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH. Cancer Chemother Pharmacol. 1994; 34(2):125-32. DOI: 10.1007/BF00685929. View

19.

Zhu Y, Zhou Y, Shi J . Post-slippage multinucleation renders cytotoxic variation in anti-mitotic drugs that target the microtubules or mitotic spindle. Cell Cycle. 2014; 13(11):1756-64. PMC: 4111722. DOI: 10.4161/cc.28672. View

20.

Yang H, Ganguly A, Cabral F . Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs. J Biol Chem. 2010; 285(42):32242-50. PMC: 2952225. DOI: 10.1074/jbc.M110.160820. View